arBtrage CAPITALIZING MARKETS — checking… Sign in Sign up
Calendar /

CytomX Therapeutics, Inc.

CTMX Health Care Biotechnology: Pharmaceutical Preparations
$2.32
▼ -3.3% Today
as of Oct 23, 16:47 ET
Last 30 days -27.50% Sep 14 → Oct 23
$2.15 $2.43 $2.72 $3.00 $3.28 Sep 14 Sep 22 Sep 30 Oct 07 Oct 15 Oct 23
Open
$2.38
High
$2.47
Low
$2.37
Volume
$2M
Avg Vol
$4M
Mkt Cap
$556M
P/E (TTM)
—
Beta
—
52w High
$8.21
52w Low
$2.20
Div Yield
—
Shares Out
—

Recent Press Releases & News last 60 days · 3 items

Sep 1 · 12:00 PR GlobeNewswire
CytomX Therapeutics to Present at Upcoming September Investor Conferences
Aug 27 · 12:54 MT Newswires
CytomX's Varseta-M Receives FDA Fast-Track Designation to Treat Colorectal Cancer
Aug 27 · 12:00 PR GlobeNewswire
CytomX Therapeutics Announces FDA Fast Track Designation for Varsetatug masetecan (“Varseta-M”) for Relapsed/Refractory Metastatic Colorectal Cancer (R/R mCRC)

CTMX earnings at a glance

CytomX Therapeutics, Inc. (CTMX) is scheduled to report earnings on Thursday, November 5, 2026 — in 13 days. Analysts expect earnings per share of -$0.09, compared with -$0.09 in the same quarter last year (+0%). The options market is pricing a move of about ±26.3% after the report, a range of roughly $1.71 to $2.93 from today's $2.32. Over its last 6 reports the stock rose the next day 4 times and fell 2, moving ±33.7% on average; after the most recent report on Aug 6, 2026 it moved +2.7%. That means options currently expect less movement than CTMX has typically delivered. CTMX beat the consensus EPS estimate in 4 of its last 6 reported quarters. Implied volatility is currently 222%. The share price of $2.32 sits near its 52-week low.

More Health Care stocks · All stocks · Earnings calendar

Overview

52-week range
$2.20
$8.21
2% of range
Avg surprise (last 6)
-17.2%
Avg reaction (last 6)
+29.0%
67% positive
Latest IV / EM
222%
EM ±26.3% · $2 · Oct 16

Earnings trends

EPS — actual vs estimate Actual Estimate
$-0.22$-0.10$0.02$0.15$0.27 Actual $0.27Est $0.18Est $-0.06Actual $-0.09Est $-0.04Actual $-0.22Est $-0.08Actual $-0.10Est $-0.14Actual $-0.09Est $-0.11 Mar/2025Jun/2025Sep/20258KMar/2026Jun/2026
Revenue vs Net Income Revenue Net income
$-21M$-2M$16M$35M$53M Sep 24Mar 25Jun 25Sep 25Mar 26Jun 26

Earnings history

DatePeriodActual EPSEstSurpriseYoY %ΔDay reactSource
Thu Aug 6, 2026Jun/2026 $-0.09 $-0.11 +18.2% — +2.7% earnings
Thu May 7, 2026Mar/2026 $-0.10 $-0.14 +28.6% -137.0% -0.5% earnings
Mon Mar 16, 20268K 2026-03-16 $-0.22 $-0.08 -175.0% — +44.2% earnings
Thu Nov 6, 2025Sep/2025 $-0.09 $-0.04 -125.0% — -13.6% earnings
Thu Aug 7, 2025Jun/2025 — $-0.06 +100.0% — +11.9% earnings
Mon May 12, 2025Mar/2025 $0.27 $0.18 +50.0% — +129.5% earnings

Upcoming

DateFiscalTimeEPS EstLY EPSYoY %Δ
Thu Nov 5, 2026Sep/2026OTHER -$0.09-$0.09 0.0%

Financials

Income statement (quarterly)

MetricJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue$1M$10M—$6M$19M$51M—$33M
Cost of revenue————————
Gross profit————————
Operating income$-24M$-20M—$-16M$-1M$23M—$4M
Net income$-21M$-18M—$-14M$-154,000$24M—$6M
EPS (diluted)————————

Balance sheet (quarterly)

MetricJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Cash & equivalents$17M$29M$13M$34M$49M$48M$38M$41M
Inventory————————
Total current assets$373M$353M$144M$149M$165M$87M$107M$124M
Total assets$381M$359M$152M$158M$175M$98M$121M$139M
Long-term debt————————
Total liabilities$79M$39M$53M$51M$55M$73M$121M$162M
Total equity$302M$320M$99M$107M$120M$25M$-456,000$-23M

Implied volatility — last 90 days

60%145%230%316%401% Jun 08 — IV 76% · EM ±10.0%Jun 09 — IV 94% · EM ±11.7%Jun 19 — IV 92% · EM ±20.3%Jun 22 — IV 102% · EM ±21.4%Jun 23 — IV 62% · EM ±12.7%Jun 24 — IV 120% · EM ±24.1%Jun 25 — IV 86% · EM ±16.8%Jun 26 — IV 151% · EM ±28.8%Jun 29 — IV 91% · EM ±16.0%Jul 02 — IV 86% · EM ±13.9%Jul 03 — IV 88% · EM ±13.7%Jul 06 — IV 81% · EM ±11.2%Jul 20 — IV 138% · EM ±32.7%Jul 21 — IV 170% · EM ±39.6%Jul 22 — IV 98% · EM ±22.5%Jul 23 — IV 140% · EM ±31.5%Jul 24 — IV 87% · EM ±19.3%Jul 27 — IV 162% · EM ±33.8%Jul 28 — IV 83% · EM ±17.1%Jul 29 — IV 118% · EM ±23.7%Jul 30 — IV 86% · EM ±16.8%Jul 31 — IV 92% · EM ±17.6%Aug 03 — IV 125% · EM ±22.1%Aug 04 — IV 147% · EM ±25.3%Aug 05 — IV 197% · EM ±32.8%Aug 06 — IV 167% · EM ±26.9%Aug 07 — IV 110% · EM ±17.1%Aug 10 — IV 189% · EM ±26.2%Aug 11 — IV 176% · EM ±23.2%Aug 12 — IV 206% · EM ±25.8%Aug 13 — IV 202% · EM ±23.9%Aug 14 — IV 224% · EM ±24.7%Aug 17 — IV 312% · EM ±26.1%Aug 18 — IV 224% · EM ±16.2%Aug 19 — IV 401% · EM ±23.7%Aug 20 — IV 323% · EM ±13.5%Aug 24 — IV 134% · EM ±28.0%Aug 26 — IV 143% · EM ±28.6%Aug 27 — IV 164% · EM ±32.2%Aug 28 — IV 171% · EM ±32.7%Aug 31 — IV 97% · EM ±17.1%Sep 01 — IV 83% · EM ±14.3%Sep 02 — IV 66% · EM ±11.0%Sep 03 — IV 118% · EM ±19.0%Sep 04 — IV 82% · EM ±12.8%Sep 07 — IV 92% · EM ±12.8%Sep 08 — IV 187% · EM ±24.7%Sep 09 — IV 214% · EM ±26.8%Sep 10 — IV 202% · EM ±23.9%Sep 11 — IV 179% · EM ±19.8%Sep 14 — IV 187% · EM ±15.6%Sep 16 — IV 398% · EM ±23.5%Sep 21 — IV 61% · EM ±12.7%Sep 22 — IV 71% · EM ±14.5%Sep 23 — IV 94% · EM ±18.8%Sep 24 — IV 88% · EM ±17.3%Sep 25 — IV 92% · EM ±17.6%Sep 28 — IV 105% · EM ±18.6%Sep 29 — IV 106% · EM ±18.2%Sep 30 — IV 165% · EM ±27.6%Oct 01 — IV 200% · EM ±32.3%Oct 02 — IV 237% · EM ±37.1%Oct 06 — IV 311% · EM ±41.0%Oct 07 — IV 250% · EM ±31.4%Oct 08 — IV 222% · EM ±26.3%

Sector peers

STTK
Shattuck Labs, Inc.
$568M $5.49-1.6%
SGMT
Sagimet Biosciences Inc.
$577M $9.58-4.1%
CAPR
Capricor Therapeutics, Inc.
$520M $5.93+0.8%
OCS
Oculis Holding AG
$508M $7.90+0.4%
PBYI
Puma Biotechnology Inc
$506M $11.02+1.1%
CBIO
Crescent Biopharma, Inc.
$501M $12.82-2.7%

CTMX earnings FAQ

When is CTMX's next earnings date?

CytomX Therapeutics, Inc. is expected to report on November 5, 2026.

What is CTMX's expected move for earnings?

Options currently price a move of about ±26.3%, or $0.61 per share either way from $2.32.

How does CTMX stock usually react to earnings?

Across the last 6 reports the average next-day move was ±33.7%, up 4 times and down 2 times.

What EPS are analysts expecting from CytomX Therapeutics, Inc.?

The consensus estimate is -$0.09 per share, versus -$0.09 a year ago.

What is CTMX's implied volatility?

CTMX's at-the-money implied volatility is about 222% based on the latest options snapshot.

View on Nasdaq ↗
🔒 Preview mode. Create a free account to unlock the full earnings calendar, all panels, heatmaps, options flow, and screener.
Sign up free → Sign in